ACR:台湾国立阳明大学研究者发现系统性红斑狼疮患者蛛网膜下腔出血风险增加

2013-05-14 ACR dxy

系统性红斑狼疮(SLE)患者自发性蛛网膜下腔出血(SAH)相对比较常见,这一现象已被重视,但是,相关的后续研究结果存在冲突。针对这一情况,来自台湾国立阳明大学和新北市双和医院、台北医学大学的YU-SHENG CHANG等人进行了一项以全体人群为基础的研究,目的是评估SLE患者发生SAH的风险。研究结果在线发布在2013年4月的《关节炎护理及研究》(Arthritis Care & Rese

系统性红斑狼疮(SLE)患者自发性蛛网膜下腔出血(SAH)相对比较常见,这一现象已被重视,但是,相关的后续研究结果存在冲突。针对这一情况,来自台湾国立阳明大学和新北市双和医院、台北医学大学的YU-SHENG CHANG等人进行了一项以全体人群为基础的研究,目的是评估SLE患者发生SAH的风险。研究结果在线发布在2013年4月的《关节炎护理及研究》(Arthritis Care & Research)杂志上。作者发现,SAH是与SLE相关的罕见并发症,但其死亡率高。除高龄外,日平均激素使用量高和红细胞、血小板输注史均与SLE患者并发SAH有关。

该研究共纳入16,967位SLE患者,受试者资料均来自于2000年至2006年的台湾全民健康保险(NHI)数据库,对照组由16,967位随机筛选的年龄、性别匹配的非SLE患者组成。研究者对两组的SAH发病率进行比较。用多变量的Cox比例风险模型来评估SLE患者并发SAH的风险因素。

研究结果如下,SLE组并发SAH的风险更高,发病率之比为4.84。,尽管SLE患者更年轻,但是并发SAH后的死亡率显著高于对非SLE的SAH患者(每一百万个全民健康保险受益者)。年龄、输血小板、输红细胞、平均每日类固醇剂量>10mg 泼尼松龙或者同等剂量等均是SLE患者新发SAH的独立风险因素。

研究证实,SAH是与SLE相关的罕见并发症,但其死亡率高。除高龄外,日平均激素使用量高和红细胞、血小板输注史均与SLE患者并发SAH有关。

狼疮相关的拓展阅读:


Increased risk of subarachnoid hemorrhage in patients with systemic lupus erythematosus: a nationwide population-based study.
OBJECTIVE
A relatively common occurrence of spontaneous subarachnoid hemorrhage (SAH) in patients with systemic lupus erythematosus (SLE) has been noted; however, the subsequent studies were conflicting. This nationwide population-based study aimed to evaluate the risk of SAH in patients with SLE.
METHODS
We identified 16,967 SLE patients from the Taiwan National Health Insurance (NHI) database between 2000 and 2006, and compared the incidence rate of SAH with 16,967 randomly selected age- and sex-matched non-SLE subjects. A Cox multivariable proportional hazards model was used to evaluate the risk factors of SAH in the SLE cohort.
RESULTS
The SLE cohort had a higher risk of SAH, with an incidence rate ratio of 4.84 (P < 0.001). Despite a younger age, the mortality rate after SAH was significantly higher in the SLE cohort compared to all of the non-SLE SAH patients identified from the 1 million NHI beneficiaries (60.0% versus 38.9%; P = 0.007). Age (hazard ratio [HR] 1.03, 95% confidence interval [95% CI] 1.01-1.05), platelet transfusion (HR 2.75, 95% CI 1.46-5.17), red blood cell transfusion (HR 7.11, 95% CI 2.81-17.97), and a mean daily steroid dose >10 mg of prednisolone or equivalent (HR 4.36, 95% CI 2.19-8.68) were independent risk factors for the new onset of SAH.
CONCLUSION
This study demonstrated that SAH is a rare but associated complication of SLE with a high mortality rate. Other than age, higher mean daily steroid use and a history of platelet or red blood cell transfusion were associated with the occurrence of SAH in patients with SLE.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1654404, encodeId=d86d1654404d5, content=<a href='/topic/show?id=5ab788e81d3' target=_blank style='color:#2F92EE;'>#蛛网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88781, encryptionId=5ab788e81d3, topicName=蛛网膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=396c24497244, createdName=aliceclz, createdTime=Fri Mar 28 06:47:00 CST 2014, time=2014-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016893, encodeId=6c192016893fb, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sun Dec 08 14:47:00 CST 2013, time=2013-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032711, encodeId=516a2032e1114, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Sat Jun 29 11:47:00 CST 2013, time=2013-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387138, encodeId=2325138e13808, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Thu May 16 06:47:00 CST 2013, time=2013-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400288, encodeId=19b7140028813, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu May 16 06:47:00 CST 2013, time=2013-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436047, encodeId=da1c143604ef9, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu May 16 06:47:00 CST 2013, time=2013-05-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1654404, encodeId=d86d1654404d5, content=<a href='/topic/show?id=5ab788e81d3' target=_blank style='color:#2F92EE;'>#蛛网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88781, encryptionId=5ab788e81d3, topicName=蛛网膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=396c24497244, createdName=aliceclz, createdTime=Fri Mar 28 06:47:00 CST 2014, time=2014-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016893, encodeId=6c192016893fb, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sun Dec 08 14:47:00 CST 2013, time=2013-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032711, encodeId=516a2032e1114, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Sat Jun 29 11:47:00 CST 2013, time=2013-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387138, encodeId=2325138e13808, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Thu May 16 06:47:00 CST 2013, time=2013-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400288, encodeId=19b7140028813, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu May 16 06:47:00 CST 2013, time=2013-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436047, encodeId=da1c143604ef9, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu May 16 06:47:00 CST 2013, time=2013-05-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1654404, encodeId=d86d1654404d5, content=<a href='/topic/show?id=5ab788e81d3' target=_blank style='color:#2F92EE;'>#蛛网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88781, encryptionId=5ab788e81d3, topicName=蛛网膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=396c24497244, createdName=aliceclz, createdTime=Fri Mar 28 06:47:00 CST 2014, time=2014-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016893, encodeId=6c192016893fb, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sun Dec 08 14:47:00 CST 2013, time=2013-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032711, encodeId=516a2032e1114, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Sat Jun 29 11:47:00 CST 2013, time=2013-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387138, encodeId=2325138e13808, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Thu May 16 06:47:00 CST 2013, time=2013-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400288, encodeId=19b7140028813, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu May 16 06:47:00 CST 2013, time=2013-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436047, encodeId=da1c143604ef9, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu May 16 06:47:00 CST 2013, time=2013-05-16, status=1, ipAttribution=)]
    2013-06-29 stfoxst
  4. [GetPortalCommentsPageByObjectIdResponse(id=1654404, encodeId=d86d1654404d5, content=<a href='/topic/show?id=5ab788e81d3' target=_blank style='color:#2F92EE;'>#蛛网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88781, encryptionId=5ab788e81d3, topicName=蛛网膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=396c24497244, createdName=aliceclz, createdTime=Fri Mar 28 06:47:00 CST 2014, time=2014-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016893, encodeId=6c192016893fb, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sun Dec 08 14:47:00 CST 2013, time=2013-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032711, encodeId=516a2032e1114, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Sat Jun 29 11:47:00 CST 2013, time=2013-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387138, encodeId=2325138e13808, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Thu May 16 06:47:00 CST 2013, time=2013-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400288, encodeId=19b7140028813, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu May 16 06:47:00 CST 2013, time=2013-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436047, encodeId=da1c143604ef9, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu May 16 06:47:00 CST 2013, time=2013-05-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1654404, encodeId=d86d1654404d5, content=<a href='/topic/show?id=5ab788e81d3' target=_blank style='color:#2F92EE;'>#蛛网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88781, encryptionId=5ab788e81d3, topicName=蛛网膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=396c24497244, createdName=aliceclz, createdTime=Fri Mar 28 06:47:00 CST 2014, time=2014-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016893, encodeId=6c192016893fb, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sun Dec 08 14:47:00 CST 2013, time=2013-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032711, encodeId=516a2032e1114, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Sat Jun 29 11:47:00 CST 2013, time=2013-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387138, encodeId=2325138e13808, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Thu May 16 06:47:00 CST 2013, time=2013-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400288, encodeId=19b7140028813, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu May 16 06:47:00 CST 2013, time=2013-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436047, encodeId=da1c143604ef9, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu May 16 06:47:00 CST 2013, time=2013-05-16, status=1, ipAttribution=)]
    2013-05-16 10518094zz
  6. [GetPortalCommentsPageByObjectIdResponse(id=1654404, encodeId=d86d1654404d5, content=<a href='/topic/show?id=5ab788e81d3' target=_blank style='color:#2F92EE;'>#蛛网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88781, encryptionId=5ab788e81d3, topicName=蛛网膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=396c24497244, createdName=aliceclz, createdTime=Fri Mar 28 06:47:00 CST 2014, time=2014-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016893, encodeId=6c192016893fb, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sun Dec 08 14:47:00 CST 2013, time=2013-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032711, encodeId=516a2032e1114, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Sat Jun 29 11:47:00 CST 2013, time=2013-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387138, encodeId=2325138e13808, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Thu May 16 06:47:00 CST 2013, time=2013-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400288, encodeId=19b7140028813, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu May 16 06:47:00 CST 2013, time=2013-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436047, encodeId=da1c143604ef9, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu May 16 06:47:00 CST 2013, time=2013-05-16, status=1, ipAttribution=)]
    2013-05-16 zhouqu_8

相关资讯

回顾系统性红斑狼疮的十年研究进展

  2010年9月,《风湿病年鉴》[Ann Rheu Dis 2010,69(9):1603]刊发了希腊和美国学者的一篇联合综述文章,从病因、发病机制、病程和转归等数个方面对系统性红斑狼疮(SLE)在过去十年间的进展情况进行了全面回顾,非常有学习价值。          

孙凌云:系统性红斑狼疮(SLE)药物治疗研究进展

    南京大学医学院附属鼓楼医院孙凌云教授为本报记者介绍了本次会议中系统性红斑狼疮(SLE)相关内容。① 在病因学研究中,微小RNA-146A、干扰素(IFN)、长寿浆细胞等一些参与SLE发病的新分子、细胞等被发现并得到进一步研究;② SLE诊断进展主要见于神经精神狼疮领域,包括影像学评估和生物标志物的研究;③ 在治疗方面,狼疮肾炎(LN)诊疗的细节问题

系统性红斑狼疮合并血栓性血小板减少性紫癜的临床特点

  中国医学科学院北京协和医学院崔静、朱铁楠和张奉春等探讨了系统性红斑狼疮(SLE)合并血栓性血小板减少性紫癜 (TTP) 的临床特点、诊断及治疗。结果发现,SLE与TTP临床表现相似,多次重复血涂片检查对早期明确诊断SLE合并TTP十分重要。SLE合并TTP者肾功能损害程度比单纯TTP或SLE者更为严重,早期诊断并及时应用糖皮质激素联合血浆置换有助于改善患者的预后。相关论文在

Lupus:血清肿瘤坏死因子-α水平与系统性红斑狼疮患者的生活质量和抑郁症状相关

尽管系统性红斑狼疮(SLE)患者的健康相关的生活质量(HRQoL)比健康人更差,抑郁状态更严重,但是,重要促炎性细胞因子,比如,肿瘤坏死因子-α(TNF-α),对不良心理因素的重要性仍不清楚。针对这一情况,来自新加坡国立大学杨潞龄医学院风湿免疫科的A Mak等进行了一项研究。该研究的目的是探讨SLE患者抑郁症状,HRQoL和狼疮相关促炎性细胞因子有关。研究结果在线发布在2013年3月的《狼疮》(L

PLoS ONE:左建平等青蒿素衍生物治疗系统性红斑狼疮研究再获进展

系统性红斑狼疮 (systemic lupus erythematosus, SLE)是自身免疫介导的、多系统累及的致死性自身免疫病。多年来,由于受病理机制复杂、治疗靶点缺乏、相关疾病动物模型周期过长等因素的制约,SLE治疗药物的研究进展缓慢。 中科院上海药物研究所左建平研究员课题组多年来致力于SLE治疗药物的研究,并取得了一定的研究成果。水溶性青蒿素衍生物SM934作为治疗SLE候选新药,